Group 1 - The main reason for the performance improvement is the collaboration between the company and DoveTree Medicines LLC, utilizing an end-to-end AI drug discovery platform and "AI + robotics" technology [1] - The collaboration has led to significant revenue growth, with a $51 million upfront payment recognized as revenue for the mid-2025 period, contributing importantly to the reported revenue [1] Group 2 - The company expects its consolidated revenue for the mid-2025 period to be no less than RMB 500 million, representing an increase of at least 387% compared to RMB 103 million in the same period of 2024 [2] - The company anticipates turning a profit, with a projected net profit of no less than RMB 50 million for the mid-2025 period, reversing a net loss of RMB 1.238 billion in the same period of 2024 [2] - Adjusted net loss is expected to shift from RMB 251 million in 2024 to an adjusted net profit of no less than RMB 120 million in the mid-2025 period [2]
晶泰控股预计中期综合收益同比增加至少约387%
Zheng Quan Shi Bao Wang·2025-08-12 00:37